*Data on file (K183109, K200663, K202431, K213455)
Sean has over 15 years of experience in the medical device industry holding senior sales leadership positions at both private and public companies.
Prior to joining ControlRad as Vice President of Sales, Sean was the National Sales Manager at Cartiva Inc., a venture-backed company that developed and marketed medical devices for the treatment of osteoarthritis. While there, he was responsible for the commercial launch of the first-ever FDA PMA-approved Cartiva Synthetic Cartilage Implant for the treatment of great toe arthritis. He was part of the leadership team that executed a successful exit to Wright Medical in October 2018. Earlier in his career, Mr. Finnerty held sales leadership positions with Stryker, Carticept Medical Inc., and Integra LifeSciences and has extensive experience in building high performing teams and growing businesses in the orthopedic market.
Mr. Finnerty holds a Bachelor of Science from the United States Naval Academy in Annapolis, MD and is a combat veteran.
Prior to TPM, Mr. Krymka was the Vice President of Research and Development of R&DEEN System Design House. Earlier in his career, he was AVP of Ceragon Networks Ltd. (NASDAQ: CRNT), who specializes in wireless backhaul solutions.
Mr. Krymka holds a B.Sc. degree in Electrical & Electronic Engineering from the Technion – Israel Institute of Technology.
Dr. Nichtberger is a cardiologist and serial entrepreneur who was the founding chairman and CEO of ControlRad. He is currently Chairman, CEO and co-founder of Cabaletta Bio (CABA; Nasdaq). As an adjunct professor at the Wharton School, he leads the Vagelos Life Sciences & Management capstone course on healthcare company formation, financing and leadership. From 2004 to 2011, he was the CEO of Tengion, advancing novel regenerative medicine products from early stage research to late stage clinical trials.
Previously, Dr. Nichtberger held senior strategic and operating roles at Merck including as head of global marketing where he was instrumental in several corporate licensing, divestiture, and product acquisition projects.
From 1984 until 2006, Dr. Nichtberger founded and led a profitable, private company that licensed intellectual property in the field of internet-based paperless couponing. In 2008, Dr. Nichtberger was awarded the National Ernst and Young Entrepreneur of the Year Award in the Emerging Company Category.
Prior to founding Cartiva, Mr. Patrick was President and CEO of Proxima Therapeutics, Inc., a medical device company that developed and marketed innovative local radiation delivery systems for the treatment of cancerous tumors. Proxima was acquired by Cytyc Corporation in March 2005 for approximately $187 million.
Prior to co-founding Proxima Therapeutics, he was President of Gesco International and prior to that, ran two high-growth divisions for McGaw Inc., an oncology drug provider. He also held a number of sales and sales management positions at American Hospital Supply. He has served on the Board of Directors of ADVAMED, the Georgia Tech Coulter Grant Committee, Georgia Bio and was a member of the Directors Circle at Yerkes National Primate Research Center. He is an inventor on numerous patents related to orthopedic implants, automated drug delivery systems and localized radiation delivery systems. Mr. Patrick earned his BA in Zoology from Miami University in Ohio.
Mr. Kirkpatrick is a Partner at Questa Capital, a healthcare-focused venture growth equity investment firm. He brings over a decade of healthcare investing and investment banking experience. At Questa, he focuses on sourcing and executing new investment opportunities and monitoring portfolio companies.
Prior to joining Questa, Mr. Kirkpatrick was a Vice President at Angelo, Gordon & Co., where he focused on growth-oriented private equity transactions in the healthcare, consumer and specialty finance sectors. Mr. Kirkpatrick previously worked at Harris Williams & Co. as an investment banking analyst focused on the healthcare sector, where he was involved in dozens of transactions.
Mr. Kirkpatrick holds a B.S. in Commerce from the McIntire School of Commerce at the University of Virginia.
Ms. Lazarus began her career at GE in the Manufacturing Management Program where she gained experience in sourcing, supplier quality, logistics, and manufacturing. Ms. Lazarus went on to hold a variety of roles including General Manager of the Interventional Service business overseeing products in Cardiology, Angiography, Neurology, Electrophysiology & IT. She also led GE Healthcare’s Global Service Integration initiative before joining ArchPoint Consulting, as a Partner and later Managing Director. There, her client focus included strategic planning, M&A and post-merger integrations for companies in healthcare, pharma, energy, emergency services and advanced engineering materials.
Ms. Lazarus holds an Executive MBA from Northwestern’s Kellogg School of Management and a B.S. in Industrial Engineering from Georgia Tech.
Previously he served as Managing Director at Medtown Ventures, LLC., and as President and CEO of Amniox Medical. Earlier in his career, Mr. Fair served in leadership roles at MedShape Solutions, St. Francis Medical Technologies and DePuy Spine.
Mr. Fair currently sits on the Institute for Bioengineering and Bioscience Advisory Board of the Georgia Institute of Technology as well as several privately held medical and regenerative medicine technology companies. Mr. Fair graduated from the University of Richmond Robins School of Business.
Mr. Mirabella graduated from Polytechnic Institute of Brooklyn with a B.S. in Aerospace Engineering and Applied Mechanics. While working in the aerospace business for McDonnell Douglas and Martin Marietta, Mr. Mirabella earned a Masters in Mechanical Engineering at the University of Central Florida and holds four patents in GE’s CT imaging business.
Mr. Bailliard has held a variety of key leadership roles in both public and private multi-national innovative companies. A Mechanical Engineer by training, he started his career designing medical devices at Genzyme Surgical and then transitioned to GE Healthcare in a Leadership Training program. While at GE, he held various sales and management positions ultimately becoming responsible for Americas X-ray Sales operations where he restored double-digit growth. Mr. Bailliard then joined a privately-held company launching an innovative imaging product in the breast cancer market, Naviscan Inc., serving as Executive Vice President Global Sales and Marketing. Mr. Bailliard then was appointed President of Mauna Kea Technologies Inc. where he was responsible for developing and growing a business introducing a disruptive imaging technology in gastroenterology, pulmonology and surgery.
Mr. Bailliard holds an Executive MBA from Emory University and a B.S. in Mechanical Engineering from Georgia Tech.
Most recently, Mr. Melman was the Vice President of R&D and Chief Operating Officer at Deep Breeze, a privately-held company developing respiratory diagnostics and home-monitoring systems. Prior to that, Mr. Melman was Vice President of R&D at Spectrum Dynamics where they developed and commercialized the first successful CZT-based medical nuclear camera. Mr. Melman was also Vice President of R&D at Orex Computed Radiology Ltd. developing CR medical systems. For 15 years prior, Mr. Melman was Director of R&D at Scitex Corporation during where he developed scanners and digital cameras. Mr. Melman also developed digital angiography systems at Elscint, Ltd. In addition, he co-founded and managed InfoBit Ltd. and JetPic Inc., two start-up companies specializing in software solutions for knowledge management and marketing tools.
Mr. Melman is the author or co-author of 30 patents and patent applications. He holds a M.Sc. degree in Applied Physics from The Hebrew University in Jerusalem, Israel, and is a graduate of the Lahav Senior Management Course at the Recanati School of Management, Tel Aviv University. Mr. Melman also served as a pilot in the Israeli Air Force.
Prior to Cartiva, Mr. Pizzo was Chief Financial Officer of Proxima Therapeutics, Inc., a venture-backed medical device company that developed and marketed innovative radiation delivery systems. Proxima was acquired by Cytyc Corporation in 2005. Earlier in his career, he was Chief Financial Officer of Serologicals Corporation, a publicly-traded life science company.
Mr. Pizzo currently serves on the board of directors of Alimera Sciences, Inc. (Nasdaq: ALIM) where he chairs the audit committee and is a member of the nominating and corporate governance committee. Mr. Pizzo graduated from Washington and Lee University.